senescence-associated secretory phenotype (SASP)
(Redirected from Senescence-associated secretory phenotype)
Etiology
- associated disorders
* strongly associated with sarcopenia [1-4]
* not associated with sarcopenia[5][6]
Pathology
- overexpression of the senescence-associated secretory phenotype (SASP) leads to cellular senescence
- cellular senescence contributes to sarcopenia through the accumulation of senescent cells in skeletal muscle, which secrete proinflammatory cytokines, & other bioactive molecules [1-3]
- SASP from senescent mesenchymal stem cells narrows human myotube diameter & inhibits myoblast fusion, impairing muscle regeneration[4]
- SASP proteins including IGF-15, IGFBP-2 & cystatin-C are associated with inflammatory markers & measures of physical function such as grip strength & gait speed[7]
- also see circulating plasma factors in cellular senescence
More general terms
References
- ↑ He Y, Xie W, Li H, Jin H, Zhang Y, Li Y. Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential. Front Cell Dev Biol. 2022 Jan 10;9:793088. doi:http://dx.doi.org/ 10.3389/fcell.2021.793088. eCollection 2021. PMID: https://pubmed.ncbi.nlm.nih.gov/35083219 PMCID: PMC8784872 Free PMC article. Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC8784872/
- ↑ Huang Y, Wang C, Cui H, Sun G, Qi X, Yao X. Mitochondrial dysfunction in age-related sarcopenia: mechanistic insights, diagnostic advances, and therapeutic prospects. Front Cell Dev Biol. 2025 Oct 3;13:1590524. PMID: https://pubmed.ncbi.nlm.nih.gov/41113460 PMCID: PMC12531180 Free PMC article. Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12531180/
- ↑ Forman DE, Kuchel GA, Newman JC et al Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. J Am Coll Cardiol. 2023 Aug 15;82(7):631-647. doi:http://dx.doi.org/ 10.1016/j.jacc.2023.05.038. Epub 2023 Jun 28. PMID: https://pubmed.ncbi.nlm.nih.gov/37389519 PMCID: PMC10414756 Free PMC article. Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC10414756/
- ↑ 4.0 4.1 Ishii KA, Hashimoto R, Umeda C, Hosoyama T, Watanabe K. An in vitro model to study molecular pathogenesis of sarcopenia established by a SASP-dependent human myotube culture. PLoS One. 2025 Jul 7;20(7):e0326968. PMID: https://pubmed.ncbi.nlm.nih.gov/40623060 PMCID: PMC12233260 Free PMC article. https://pmc.ncbi.nlm.nih.gov/articles/PMC12233260/
- ↑ 5.0 5.1 Aslam MA, Ma EB, Huh JY. Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors. Metabolism. 2023 Dec;149:155711. doi:http://dx.doi.org/ 10.1016/j.metabol.2023.155711. Epub 2023 Oct 21. PMID: https://pubmed.ncbi.nlm.nih.gov/37871831 Review.
- ↑ 6.0 6.1 Chen LK, Woo J, Assantachai P et al Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. PMID: https://pubmed.ncbi.nlm.nih.gov/32033882
- ↑ 7.0 7.1 Evans DS, Young D, Tanaka T et al Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits. J Gerontol A Biol Sci Med Sci. 2024 Mar 1;79(3):glad265. PMID: https://pubmed.ncbi.nlm.nih.gov/37982669 PMCID: PMC10876076 Free PMC article. https://pmc.ncbi.nlm.nih.gov/articles/PMC10876076/